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Summary
Background Breast cancer is the second leading cause of death from cancer in women in sub-Saharan Africa, yet there 
are few well characterised large-scale survival studies with complete follow-up data. We aimed to provide robust 
survival estimates in women in this setting and apportion the survival gaps.
Methods The African Breast Cancer-Disparities in Outcomes (ABC-DO) prospective cohort study was done at eight 
hospitals across five sub-Saharan African countries (Namibia, Nigeria, South Africa, Uganda, and Zambia). We 
prospectively recruited women (aged ≥18 years) who attended these hospitals with suspected breast cancer. Women 
were actively followed up by use of a telephone call once every 3 months, and a mobile health application was used to 
keep a dynamic record of follow-up calls due. We collected detailed sociodemographic, clinical, and treatment data. 
The primary outcome was 3-year overall survival, analysed by use of flexible proportional mortality models, and we 
predicted survival under scenarios of modified distributions of risk factors.
Findings Between Sept 8, 2014, and Dec 31, 2017, 2313 women were recruited from these eight hospitals, of whom 
85 did not have breast cancer. Of the remaining 2228 women with breast cancer, 58 women with previous treatment 
or recurrence, and 14 women from small racial groups (white and Asian women in South Africa), were excluded. Of 
the 2156 women analysed, 1840 (85%) were histologically confirmed, 129 (6%) were cytologically confirmed, and 
187 (9%) were clinically confirmed to have breast cancer. 2156 (97%) women were followed up for up to 3 years or up 
to Jan 1, 2019, whichever was earlier. Up to this date, 879 (41%) of these women had died, 1118 (52%) were alive, and 
159 (7%) were censored early. 3-year overall survival was 50% (95% CI 48–53), but we observed variations in 3-year 
survival between different races in Namibia (from 90% in white women to 56% in Black women) and in South Africa 
(from 76% in mixed-race women to 59% in Black women), and between different countries (44–47% in Uganda and 
Zambia vs 36% in Nigeria). 215 (10%) of all women had died within 6 months of diagnosis, but 3-year overall survival 
remained low in women who survived to this timepoint (58%). Among survival determinants, improvements in early 
diagnosis and treatment were predicted to contribute to the largest increases in survival, with a combined absolute 
increase in survival of up to 22% in Nigeria, Zambia, and Uganda, when compared with the contributions of other 
factors (such as HIV or aggressive subtypes). 
Interpretation Large variations in breast cancer survival in sub-Saharan African countries indicate that improvements 
are possible. At least a third of the projected 416 000 breast cancer deaths that will occur in this region in the next 
decade could be prevented through achievable downstaging and improvements in treatment. Improving survival in 
socially disadvantaged women warrants special attention.
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Introduction
Breast cancer and cervical cancer constituted half of all 
new cases of cancer in women in sub-Saharan Africa in 
2018.1 There are fewer preventive approaches for breast 
cancer than for cervical cancer, thus improving breast 
cancer survival is an urgent priority to reduce the 
increasing mortality burden, projected to reach 
112 000 deaths in 2040.1 Breast cancer has the potential 
for a good prognosis, through multimodal treatments 
for early-stage disease. The 5-year survival of women 
with breast cancer (of all cancer stages) is 85–90% in 
high-income countries,2 although 5-year survival is lower 
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in Black women (80%) than in white women in the 
USA,3 and it is lower in women with hormone receptor-
negative tumours than in those with hormone receptor-
positive tumours.4 These survival estimates contrast 
with those of women with breast cancer in sub-Saharan 
Africa (appendix pp 2–3). The compiled population-
based survival estimates from the International Agency 
for Research on Cancer (now two decades old),5 the 
CONCORD-3 study,2 and the African Cancer Registry 
Network (AFCRN)6 cover 13 of 48 sub-Saharan African 
countries. The 5-year survival estimates in these 
reports2,5,6 range from less than 20% survival in Mali and 
The Gambia, to 35–50% in Uganda, and to 85% in 
Mauritius. Many of these sur vival estimates had 
unknown selection biases and substantial losses to 
follow-up of 20–40% at 2–3 years.6–8 Another important 
limitation of these reports is the scarce clinical, 
histological, epidemiological, and treatment data. Poor 
survival in sub-Saharan Africa has been associated 
with late diagnosis, aggressive tumour subtypes, a young 
age (ie, <30 years) at diagnosis, being HIV-positive, 
and suboptimal treatment,6,9–11 but a comprehensive 
estimation of the combined quantitative impact of these 
factors on survival is missing.
Herein, we report on survival in the African Breast 
Cancer-Disparities in Outcomes (ABC-DO) breast cancer 
cohort during 3 years of follow-up, and we provide 
estimates of the survival gains associated with modifying 
the drivers of poor prognosis, with the aim of informing 
effective actions to reduce future deaths due to breast 
cancer. We intended that our estimates of survival gains 
associated with modifying risk factor distributions would 
be based on the survival effects observed in the ABC-DO 
cohort only. Thus, unlike previous models,12 our predic-
tions would not rely on assumptions derived from high-
income settings.
Methods
Study design and participants
This prospective cohort study was done at eight hospitals 
across five sub-Saharan African countries (Namibia, 
Nigeria, South Africa, Uganda, and Zambia). We pros-
pec tively recruited women (aged ≥18 years) who attended 
these hospitals with suspected breast cancer, typically 
based on symptoms such as a breast mass, nipple 
retraction, or discharge and skin changes (appendix p 4). 
Per protocol,13 women were recruited irrespective of 
any treatment subsequently received, race, residence, or 
insurance status. Recruitment centres (ie, hospitals) 
and their catchment populations are provided in the 
appendix (pp 4–5). All hospitals included in the study 
could offer surgery and chemotherapy, and most were 
tertiary public hospitals. Hospitals located in the 
Namibian, Ugandan, and Zambian capitals were the only 
hospitals in the country with radiation oncology units. In 
Nigeria, recruitment was done at two tertiary public 
hospitals in the states of Imo and Abia (each with a 
population of >4 million people) and at an 18-bed private 
hospital in Aba. These three hospitals provide surgery 
and chemotherapy and can refer patients for radio therapy. 
The South African hospital located in Soweto, which has 
a population of approximately 2 million people, is part of 
Research in context
Evidence before this study
We searched PubMed using the search terms “breast cancer”, 
“survival” and “sub-Saharan Africa” to identify studies published 
between database inception up to June 1, 2019, with no 
language restrictions. We identified 20 studies that included 
breast cancer survival estimates in sub-Saharan Africa. 
Our review revealed large variations in breast cancer survival in 
this region, ranging from less than 20% to more than 90% at 
5 years. However, many of the studies identified have limited 
value when informing strategies to improve survival because 
they are outdated, have excessive losses to follow-up, 
and because of sparse epidemiologic, clinical, or therapeutic data. 
Added value of this study 
The African Breast Cancer-Disparities in Outcomes study is a 
hospital-based breast cancer cohort of 2228 women 
prospectively recruited in 2014–17 in five sub-Saharan Africa 
countries. Detailed epidemiological and clinical data on this 
cohort is being collected with a successfully implemented 
mobile health application-based follow-up protocol, in which 
participants are followed up once every 3 months. In public 
sector settings, crude overall survival in women at 3 years after 
diagnosis varied substantially, with an overall survival of 90% in 
white Namibian women, 69–76% in mixed-race Namibian and 
South African women, 55–59% in black Namibian and 
South African women, 44–47% in Ugandan and Zambian 
women, and 36% in Nigerian women. These differences were 
largely accounted for by prognostic factors. The largest survival 
gains can be achieved through near equal contributions of 
earlier diagnosis and improved treatment, and if these factors 
were combined, they would lead to a 28–37% reduction in the 
number of deaths in black women in a given setting. A young 
age at diagnosis and a high prevalence of HIV represented a 
small contribution (<2% each) to low survival in these 
sub-Saharan African countries.
Implications of all the available evidence
A projected 416 000 women will die from breast cancer in 
sub-Saharan Africa in 2020–29, which is an excessive mortality 
toll for a cancer that is potentially curable if diagnosed and 
treated early. The results of our study suggest that, through 
downstaging of symptomatic disease and treatment 
improvements, a substantial proportion (ie, at least a third) of 
deaths from breast cancer could be averted.
See Online for appendix
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another ongoing cohort study.14 The ABC-DO study was 
approved by all institutional ethics committees (appendix 
p 1), and all women provided written or thumbprint 
informed consent, witnessed by the study interviewer.
Procedures
Participants completed an interviewer-administered 
questionnaire at recruitment, consented to allow the 
study team access to their clinical data, and took part in 
regular follow-up. The questionnaire collected detailed 
data on sociodemographic factors, including education 
level, the nine amenities used to generate site-specific 
tertiles of socioeconomic position, breast cancer aware-
ness, cohabitation (yes or no), and residential area 
(urban or rural). Participants were tested for HIV 
infection in South Africa, but HIV infection status was 
self-reported (yes, no, or not known) in all other 
countries.
Clinical data included breast cancer stage, and if 
documented, grade and receptor subtype. The presence 
of oestrogen receptors and progesterone receptors (ie, 
hormone receptors) was defined as greater than 1% 
immunohisto chemical staining for these receptors, 
and the presence of human epidermal growth factor 
Receptor 2 (HER2) was defined as a score of 3 by 
immunohistochemistry or a positive fluorescence in-
situ hybridisation result (defined as a HER2:CEP17 
fluorescence ratio of >2) Information on treatment was 
sourced from medical records and women’s self-
reports.15 We obtained data on life-prolonging treat-
ments, considered as surgical removal of the tumour, 
systemic therapy (defined has having had chemotherapy, 
or endocrine therapy, or both), or both received within 
12 months of diagnosis.
Outcomes
The primary outcome was 3-year overall survival, which 
was measured by ascertaining vital status by use of a 
telephone call to the participant or their next of kin once 
every 3 months. The dynamic list of participants who 
were due follow-up calls and their contact details were 
managed by use of a mobile health application (appendix 
p 13). If a woman was attending the hospital for routine 
clinical management (that was not organised by the 
study), this information was used to update her vital 
status.
Statistical analysis
We analysed 3-year overall survival on a time-since-
diagnosis scale. Follow-up time commenced on the date 
of diagnosis, which was defined as the date of biopsy 
according to the European Network of Cancer Registry 
guidelines.16 If this date was unavailable, the date of the 
histology report or the recruitment date was used. 
Follow-up continued to the earliest of the date of death, 
the date on which the participant was last known to be 
alive, 3 years after diagnosis, or Jan 1, 2019, whichever 
came first. Crude Kaplan-Meier survival curves were 
used to visually represent the results. We calculated net 
survival, accounting for background age-specific national 
mortality,17,18 and estimated age-standardised net survival 
to the International Cancer Survival Standard19 (see 
appendix [p 1] for further details). Age-adjusted and 
cancer stage-adjusted determinants of survival were 
examined by use of Cox proportional hazards models, 
stratified by group and by flexible parametric survival 
models (group-adjusted), which were used to predict 
group-specific 3-year survival under seven cumulative 
scenarios. The first scenario was downstaging to a stage-
at-diagnosis distribution of 35% of patients at stage I 
or IIA, 25% at stage IIB, 15% at stage IIIA, 10% at 
stage IIIB, 7% at stage IIIC, and 8% at stage IV. 
This distribution was considered achievable, since it 
represented a marginal improvement in the stage 
distribution from that observed in Black South African 
women (who are not screened for breast cancer) and is 
similar to previous models.12 For racial groups in whom 
this distribution had already been achieved, downstaging 
to 60% stage I or IIA, 20% stage IIB, 5% stage IIIA, 
5% stage IIIB, 5% stage IIIC, and 5% stage IV was 
applied. Survival predictions for the improved cancer 
stage distribution assumed that treatment was provided 
at the observed site and stage-specific treated proportions. 
The second scenario was of all women receiving systemic 
therapy and surgery, with treatment effects restricted to 
those observed for non-metastatic disease. Increased 
mortality associated with no treatment in metastatic 
patients was interpreted as capturing a decision not to 
treat patients with stage IV disease or terminally ill 
patients, as opposed to an effect of the absence of 
treatment when recommended. The third scenario was 
reducing social inequalities (ie, education level) that lead 
to survival deficits, such that the survival of women 
grouped by education level (none, primary, or secondary) 
was shifted to that of women in the level above. The final 
three scenarios were removing survival deficits associated 
with HIV infection; a young age at diagnosis (<30 years); 
and non-hormone receptor-positive, HER2-negative 
tumours (when tumour subtypes were known). Hormone 
receptor-positive tumours were those in which either the 
oestrogen receptor or the progesterone receptor was 
positive.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results 
Between Sept 8, 2014, and Dec 31, 2017, 2313 women were 
recruited from eight hospitals, of whom 85 did not have 
breast cancer. Of the remaining 2228 women with breast 
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cancer, 58 women with previous treatment or recurrence, 
and 14 women from small racial groups (white and 
Asian women in South Africa), were excluded. Of the 
2156 women analysed, 1840 (85%) were histologically 
confirmed, 129 (6%) were cytologically confirmed, and 
187 (9%) were clinically confirmed to have breast cancer. 
TNM stage16 was primarily assessed clinically, with the aid 
of ultrasound (654 [43%] of 1466 women), x-ray (478 [33%]), 
or surgical information (220 [15%]), and rarely by bone 
scan (four [<1%]), CT scan (28 [<1%]), or MRI (five [<1%]). 
We excluded minority racial groups of women in South 
Africa (six Asian women and eight white women), seven 
women with no follow-up data, and 51 women with 
potentially recurrent cancer or who had received previous 
treatment. The remaining 2156 (97%) women were 
categorised into nine country-specific and race-specific 
groups: three in Namibia (white, mixed-race, or Black 
women), two in South Africa (Black or mixed-race 
women), one in Uganda, and one in Zambia, in addition 
to two groups in Nigeria that were stratified by public or 
private hospitals, but not race. Mean age at breast cancer 
diagnosis ranged from 45 years in women recruited 
from the Nigerian private hospital to 59 years in white 
Namibian women (appendix pp 4–5). 73 (76%) of 
Total (all) Namibia South Africa Uganda (all) Zambia (all) Nigeria
White Mixed race Black Black Mixed race Public sector Private clinic
Number of women 
followed up
2156 60 37 384 635 36 421 198 309 76























Status at end of follow-up†
Died 879 (41%) 6 (10%) 10 (27%) 152 (40%) 196 (31%) 8 (2%) 211 (50%) 73 (37%) 169 (55%) 54 (71%)
Administrative 
censoring at 3 years 




668 (31%) 11 (18%) 13 (35%) 60 (16%) 309 (49%) 23 (64%) 66 (16%) 79 (40%) 91 (29%) 16 (21%)
Early censoring 
(lost to follow-up)
159 (7%) 2 (3%) 0 8 (2%) 82 (13%) 2 (6%) 18 (4%) 43 (22%) 4 (1%) 0
Number of deaths during the time period since diagnosis, years
0 to <0·5 215 0 3 26 48 1 43 33 43 18
0·5 to <1 183 0 1 30 39 2 49 12 37 13
1 to <2 306 2 3 46 82 5 75 22 55 16
2 to <3 175 4 3 50 27 0 44 6 34 7
Median age at death 
(IQR), years
51 (42–62) 53 (41–65) 57 (49–64) 53 (43–66) 57 (45–66) 55 (39–63) 47 (39–57) 51 (40–69) 51 (40–60) 45 (40–51)
Number aged 
<40 years‡
181 (21%) 1 (17%) 0 26 (17%) 24 (12%) 2 (25%) 55 (26%) 16 (23%) 42 (25%) 14 (26%)
1-year survival
Crude survival 79% (77–81) 100% 87% (69–95) 82% (77–86) 86% (83–89) 92% (76–97) 74% (69–79) 74% (66–80) 70% (64–75) 56% (43–66)
Net survival§ ·· ·· 89% (77–100) 84% (79–88) 89% (86–91) ·· 76% (71–80) 75% (68–81) 72% (66–77) 57% (45–68)
Age-standardised 
net survival
·· ·· 89% 83% 89% ·· 79% 70% 71% 53%
3-year survival
Crude survival 50% (48–53) 90% (78–95) 69% (49–82) 56% (51–62) 59% (53–64) 76% (56–87) 44% (39–49) 47% (33–59) 36% (30–42) 18% (9–29)
Net survival§ ·· ·· 73% (56–90) 60% (54–66) 64% (57–70) ·· 46% (41–52) 49% (36–63) 39% (32–45) 19% (9–29)
Age-standardised 
net survival
·· ·· 72% 62% 68% ·· 52% 51% 38% 16%
3-year survival conditional on surviving to 6 months 
Crude survival 58% (55–60) 90% (78–95) 76% (56–88) 63% (57–68) 63% (57–69) 78% (58–89) 51% (46–57) 59% (41–73) 43% (36–50) 25% (13–40)
Net survival§ ·· ·· 81% (65–97) 66% (61–72) 68% (61–75) ·· 54% (48–59) 62% (46–78) 46% (38–54) 26% (13–40)
Age-standardised 
net survival
·· ·· 75% 69% 72% ·· 60% 64% 45% 20%
Data are n (%) or percentage surviving (95% CI) unless otherwise indicated. NA=not applicable. *Regardless of vital status. †End of follow-up to earliest of 3 years after diagnosis or Jan 1, 2019, whichever came 
first. ‡Expressed as a proportion of those who had died at the end of follow-up. §Net survival accounts for background age-specific national mortality in women, but was not estimated in mixed-race groups in 
South Africa because of the absence of race-specific mortality data for this minority race. 
Table: Information on deaths and patients who died and survival estimates in the ABC-DO cohort, by country and subgroup
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97 non-Black Namibian women, 321 (48%) of 669 South 
African women, 138 (36%) of 384 Black Namibian 
women, 146 (38%) of 389 Ugandan women, 68 (42%) of 
161 Zambian women, and only 77 (27%) of 283 women 
from public hospitals had stage I or II disease. 63 (85%) 
of 74 women in the Nigerian private hospital had stage III 
or stage IV disease. 
The study protocol20 proved feasible, with a median of 
3·1 months (IQR 3·0–3·8) between each follow-up 
telephone call, minimal losses to follow-up, and timely 
study notification of deaths at a median of 10 weeks 
(IQR 5–16) after the date of death. Of the 2156 women 
followed for up to 3 years, 879 (41%) died, 1118 (52%) 
were alive at administrative censoring, and 159 (7%) were 
censored early (table and appendix p 14). 809 (92%) 
deaths were reported by the participant’s next of kin, and 
records of 53 (6%) deaths were obtained from hospital 
records and 17 (2%) deaths were obtained from staff at 
Figure 1: Crude overall survival to 3 years after breast cancer diagnosis
Kaplan-Meier survival curves showing crude 3-year overall survival in 2156 women by country and race or setting (A), and by stage at diagnosis (B). Kaplan-Meier survival curves showing crude 3-year 
overall survival in 1934 women who survived for 6 months or longer, by country and race or setting (C) and stage at diagnosis (D). HRs (95% CIs) in (A) and (C) show the comparison with Namibian 
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hospices and health centres. Less than 4% of participants 
in all groups, apart from the group of Black women 
in South Africa (13%) and of women in Zambia (22%), 
were lost to follow-up (table). Losses to follow-up in 
Zambia were due to staffing issues that led to temporary 
interruption of the follow-up process. Median age at 
death was 51 years (IQR 42–62), with 181 (21%) of 
879 deaths occurring in women under the age of 40 years 
(table).
16 (0·7%) of all 2156 women were recorded as having 
stage 0 cancer and were not included in the Kaplan-Meier 
survival estimates because of the small number, but 
these patients were included in the same group as those 
with stage I or IIA cancer or with stage I, IIA, or IIB 
cancer in later analyses.
Crude 3-year survival was 50% (95% CI 48–53) in the 
entire cohort, but variations in 3-year survival were 
observed between those of different races in Namibia 
(90% [78–95] in white women, 69% [49–82] in mixed-
race women, and 56% [51–62] in Black women) and 
South Africa (76% [56–87] in mixed-race women and 
59% [53–64] in Black women), between different 
countries (44% [39–49] in Uganda, 47% [33–59] in 
Zambia, and 36% [30–42] in Nigeria), and between the 
two public sector hospitals (36% [30–42]) and the private 
clinic (18% [9–29]) in Nigeria, (table, figure 1, and 
appendix p 15). Net 3-year survival estimates were higher 
than crude estimates by 1–5% (absolute differences), and 
age-standardised net survival estimates were a further 
2–6% higher and led to a small widening of between-
group survival differences (table). Overall, 215 (10%) of 
patients in the cohort died within 6 months of diagnosis, 
reflecting the extent of advanced disease at diagnosis. 
However, crude 3-year survival conditional on surviving 
to 6 months (58%) was only marginally higher than the 
crude 3-year overall survival of the entire cohort, by 7% in 
most groups, or larger (12% higher) in Zambia (figure 1 
and table).
Cancer stage was the strongest prognostic factor, with 
3-year survival ranging from 80% in patients with 
stage IIA disease, 73% in those with stage IIB disease, 
51% in those with stage IIIA disease, 32–36% in those 
with stage IIIB or IIIC disease, and 11% in those with 
stage IV disease (figure 1 and appendix p 6 and pp 16–17). 
However, the effect of cancer stage on mortality was 
stronger between the start of follow-up to 6 months after 
diagnosis than between 6 months after diagnosis to the 
end of follow-up, with 99 (37%) deaths reported in 
271 women with stage IV disease between the start of 
follow-up and 6 months after diagnosis compared with 
five (1%) deaths in 430 women with stage I or IIA disease 
(hazard ratio [HR] 36 [95% CI 15–89]), and 134 (69%) 
deaths in 194 women with stage IV disease recorded 
between 6 months after diagnosis and the end of follow-
up compared with 66 (15%) deaths in 444 women with 
stage I or IIA disease (HR 7 [5–10]; appendix p 17). These 
results again reflect that a high proportion of women had 
advanced (ie, stage III or stage IV disease) at diagnosis. 
Deaths that occurred within 6 months of diagnosis were 
not only observed in women who were diagnosed with 
metastatic disease, but also in those recorded as having 
stage IIC and IIIB disease (appendix p 6). The effect of 
Figure 2: Age-stage adjusted HRs for 3-year all-cause mortality in all 2156 women, by age, tumour 
characteristics, HIV status, and sociodemographic characteristics 
HR=hazard ratio. Hormone receptor-positive=oestrogen receptor-positive or progesterone receptor-positive. 
Hormone receptor-negative=oestrogen receptor-negative and progesterone receptor-negative. HER2=human 
epidermal growth factor Receptor 2. *In all countries except South Africa.
HR (95% CI)Deaths/ 
total participants
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advanced cancer stage on prognosis was consistent 
across groups. However, for a given stage there remained 
absolute differences in 3-year survival of over 30% 
between groups, with the lowest 3-year survival estimates 
observed in Nigeria, Zambia, and in women with 
stage IIIB, IIIC, or IV disease in Uganda (appendix p 6). 
The effects of all other survival determinants were 
smaller in magnitude than the effect of cancer stage 
(figure 2).
Age had a U-shaped association with survival, 
characterised by lower survival in younger women 
(those aged <30 years) than in older women (those 
aged 40–49 years; HR 1·45 [95% CI 1·03–2·03]). 
The increased mortality in older women was entirely 
due to backg round mortality. After adjust ing for age 
and cancer stage, mortality was higher for poorly 
differentiated tumours versus well-differentiated 
tumours (1·49 [1·12–1·98]), for oestrogen receptor-
negative tumours versus oestrogen receptor-positive 
tumours (1·69 [1·38–2·06]), for hormone recep tor-
positive, HER2-positive tumours versus hormone recep-
 tor-positive, HER2-negative tu mours (1·17 [0·90–1·53]), 
for hormone receptor-negative, HER2-positive tumours 
versus hormone receptor-positive, HER2-negative 
tumours (1·47 [1·00–2·17]), and for triple-negative 
tumours versus hormone receptor-positive, HER2-
negative tumours (1·70 [1·32–2·18]; figure 2).
Survival differentials by social indicators (education 
and socioeconomic position) and breast cancer awareness 
were also evident, approaching two times higher 
mortality in the least educated women compared with 
the most educated women (figure 2). Absolute differences 
in race-adjusted 3-year survival between women grouped 
by education level (none, primary, secondary, and tertiary) 
were 15% in Namibia and 30% in Uganda, with smaller 
differences between groups observed in South Africa and 
Nigeria. Higher mortality was observed in women who 
did not know that breast cancer is curable compared with 
those who did (HR 1·33 [1·12–1·57]), and in those who 
lived in a rural residence compared with those who lived 
in an urban residence (1·22 [1·05–1·41]; figure 2). The 
ABC-DO study included HIV-endemic hospitals in South 
Africa, thus 315 (15%) of 2156 women in the cohort were 
HIV-positive, of whom 263 (83%) were already taking 
antiretrovirals at the time of cancer diagnosis. HIV-
positive women tended to be younger at cancer diagnosis 
(211 [67%] of 315 HIV-positive women were aged 
<50 years vs 834 [45%] of 1841 HIV-negative women) and, 
independently of age, had 1·48 times (95% CI 1·22–1·81) 
higher mortality than HIV-negative women.
Treatment varied among the five countries (appendix 
p 7). In countries where women were given chemotherapy, 
approximately three-quarters was neoadjuvant chemo-
therapy, except in Uganda, where 39% was neoadjuvant 
chemotherapy (appendix p 7). Predominant first-line regi-
mens consisted of cyclophosphamide, anthra cycline, and 
taxanes, fluorouracil, or both. Mastectomies outnumbered 
breast conserving surgery in all countries. Endocrine 
therapy (largely tamoxifen) and radiotherapy were 
provided in Namibia and South Africa. The country-
specific effects of treatment on survival were similar for 
cancer stages 0, I, or II and stage III across all countries 
(appendix p 8); compared with those who received both 
surgery and systemic therapy, mortality was higher in 
women who did not receive treatment (stage II or below 
HR 2·1 [95% CI 1·3–3·3]; stage III 2·4 [1·8–3·2]), and 
among those who received systemic therapy only 
(stage II or below 2·2 [1·4–3·5]; stage III 2·1 [1·6–2·6]). 
HRs were of larger magnitude for stage IV cancer, as 
most (60 [97%]) of the 62 women who did not receive 
treatment died (indicating terminal frailty at diagnosis) 
compared with 166 (74%) of 225 women who received 
treatment. In addition, survival differences by treatment 
group were greater for all cancer stages in the first 
6 months than beyond 6 months (appendix p 9).
Scenario-based 3-year overall survival predictions in 
public hospitals are noted (figure 3; predictions and HRs 
Figure 3: Observed and predicted 3-year survival from diagnosis (A) and conditional on surviving to 
6 months (B) at the observed distribution of prognostic factors, and under specified improved scenarios, 
by site and race, and in public hospitals only
 Above the bar showing observed 3-year survival is the predicted survival of women if the following specified added 
improvements had been made: (1) downstaging to a stage at diagnosis distribution of 35% at stage I or IIA, 25% at 
stage IIB, 15% at stage IIIA, 10% at stage IIIB, 7% at stage IIIC, and 8% at stage IV, or in Namibian white and mixed-
race women, in whom this distribution is already achieved, downstaging to a stage at diagnosis distribution of 60% 
at stage I or IIA, 20% at stage IIB, 5% at stage IIIA, 5% at stage IIIB, 5% at stage IIIC, and 5% at stage IV; (2) improving 
treatment, whereby all women receive surgery and systemic therapy; (3) reducing survival deficits associated with 
social inequalities (measured by level of education), whereby, for a given site-race group, women in each of the 
three education categories (none, primary, and secondary) have the same survival as that of women in the category 
above; (4) eliminating survival deficits associated with a HIV-positive status (5) eliminating survival deficits 
associated with being aged younger than 30 years; and (6) eliminating survival deficits associated with not having 
hormone receptor-positive, HER2-negative tumours. Survival model fits are provided in the appendix (p 10). 
HR=hazard ratio. HER2=human epidermal growth factor Receptor 2. Hormone receptor-positive=oestrogen 
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provided in the appendix pp 10–12). Predictions include 
shifting actionable factors together with the theoretical 
elimination of other factors (being aged <30 years, a HIV-
positive status, and an aggressive tumour subtype) that 
are not modifiable in themselves, however, quanti fying 
their influence on survival helps prioritise research 
efforts and defines the limits of survival improvements 
that are currently possible. The largest survival gains 
would be achieved through downstaging and improve-
ments in treatment, with these factors contributing near 
equally to a combined 18–22% absolute survival gain in 
Nigeria, Zambia, and Uganda, and contributing to 
approximately a third reduction in breast cancer deaths 
in every race or country (appendix pp 11–12). Less than 
2% of survival deficits were because of a HIV-positive 
status or a young age. In countries where tumour 
subtypes were known (ie, in Namibia and South Africa), 
up to 4% of survival deficits were attributed to tumours 
that were not hormone receptor-positive plus HER2-
negative. Independent of the aforementioned factors, 
survival disadvantages associated with social inequalities, 
as measured by education level, remained substantial 
contributors to survival deficits. These findings were 
broadly similar between the entire cohort and in women 
who survived to 6 months (figure 3). Finally, after taking 
all of these factors into account, the observed 3-year 
survival range of 39–89% reduced by a half, with 3-year 
predictions above 65% in every group, thus between-
group survival differences were attenuated. The only 
remaining unexplained group-level differences in 
survival was an estimated lower mortality in white 
Namibian women (HR 0·5 [95% CI 0·2–1·2]) and higher 
mortality in Nigerian women (1·5 [1·0–2·2]) both 
compared with Black Namibian women (appendix p 10).
Discussion
Using a large prospective cohort of women with breast 
cancer in sub-Saharan Africa, we have provided robust 
survival estimates for women who attended tertiary 
hospitals in five countries, and we have apportioned 
survival gaps into immediately actionable factors (late 
stage, treatment, and social inequalities) and other 
factors (HIV status, a young age, and tumour subtype). 
Among Black women, crude 3-year survival was 
alarmingly low, with near 40% in Nigeria, 45–50% in 
Uganda and Zambia, and 56–59% in South Africa and 
Namibia. By comparison, white Namibian women had 
a 3-year survival of 90%. Survival gap apportionment 
analyses revealed that, by contrast with the strong focus 
on implementing tailored therapies in high-income 
settings (eg, expensive anti-HER2 therapies), in the 
sub-Saharan African setting of late-stage presentation 
and inadequate therapy, a population shift to earlier 
stage at diagnosis and access to improved therapy 
would considerably improve survival, thus averting 
a third of deaths. This improvement in survival 
was predicted despite the presence of young patients, 
HIV-positive patients, and triple-negative or HER2-
positive tumours.
Three previous estimates indicated that breast cancer 
survival in Ugandan women was higher than that 
observed in our cohort (5-year survival estimates of 44%, 
53%, and 56% vs 3-year survival of 44% in our cohort) 
and one survival estimate was lower (3-year survival 
of 32%), but was subject to a 34% loss to follow-up.6,21,22 
To our knowledge, ABC-DO estimates are the first for 
Zambia. Nevertheless, our survival estimates for this 
country are similar to those of neighbouring Zimbabwe.6 
For Nigeria, ABC-DO estimates are similar to those of 
two previous studies,23,24 although, the Ibadan 5-year 
survival estimate of 98% appears implausible.2 For 
Namibia, the AFCRN population-based study6 found 
that 3-year survival in 64 women with unknown race 
was 79%, which is higher than the 3-year survival 
of 56% in Black women in the ABC-DO cohort. Racial 
differences in survival appear to be large in both Namibia 
and South Africa, albeit based on small samples, 
reflecting persisting inequalities after their histories of 
racial segregation. Prognostic factors in our study are 
consistent with those in international literature,25 
including for HIV.11 Although, HIV status in our study 
was self-reported in all countries apart from South 
Africa, which could have led to an underestimation of 
the effect of HIV on survival. In addition, similar to 
findings in high-income settings, we found that social 
inequalities in survival remained large, even when stage 
and crude treatment pathways were adjusted for. Such 
inequalities could represent residual confounding by 
cancer stage, quality, and completeness of therapy, 
implying that cancer stage and treatment effects are 
underestimated, while other pathways, such as the 
presence of comor bidities could play a role.15,26–28 Thus, 
even though it is prudent to be mindful of differences in 
breast cancer survival between different settings, races, 
and socio economic groups across sub-Saharan Africa, 
and to apply caution in extrapolating the survival 
estimates to the region or nationally, the overall picture 
of low survival needing improvement remains. Further-
more, our survival estimates refer to women who reach 
treatment centres, thus, for the many women who do 
not, survival could unfortunately be worse still.
Cancer survival estimates ideally need to be population-
based, have few losses to follow-up, and quantify 
heterogeneity by clinical and epidemiological factors. 
There are no studies for sub-Saharan Africa that meet 
these criteria. As such, although the ABC-DO study is 
hospital-based rather than population-based, our cohort is 
characterised by detailed socio-demographic and clinical 
data, with a low number of women lost to follow-up, 
enabling survival gap apportionment analyses that use 
minimal assumptions or external data, which often 
originate from high-income countries. The next of kin of 
women were the main source of information on deaths in 
our study, and the short time between death and death 
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notification to the study by the next of kin was likely to 
have increased the accuracy of the date of death. Compared 
with crude survival, higher net survival and age-
standardised net survival, of a few percent in each, show 
that the background mortality and younger age distri-
butions of populations in sub-Saharan Africa contribute to 
the low crude survival of women with breast cancer. 
Nevertheless, ranking of countries and races in terms of 
survival did not change with use of crude, net, or age-
standardised net survival. However, age-standardised net 
survival should be interpreted with caution, as the age 
distribution of the standard patient population applies a 
much higher proportion to older age groups than in the 
ABC-DO cohort (proportion of individuals aged <65 years 
in the standard population is 82% compared with 42% in 
the ABC-DO cohort).
The survival estimates among Black women in the 
ABC-DO cohort were as low, or lower, than those in 
women diagnosed in 1935–54 in Connecticut, USA (with 
a crude 3-year survival of approximately 57%),29 but they 
are considerably higher than if this disease was left 
untreated (28% at 4 years from symptom onset in women 
diagnosed in the UK from 1805 to 1933).30 The survival 
estimates of women with breast cancer in Connecticut in 
1935–5429 were before the introduction of screening or 
modern therapies, indicating that large improvements in 
survival can be made through early diagnosis of palpable 
tumours. Consistently, survival gap apportionment 
analyses done in our study identified two important areas 
that need to be strengthened, namely downstaging and 
improved treatment. These findings emphasise the 
importance of a parallel health systems approach to 
simultaneously strengthen early detection, diagnosis, 
and disease management, as recommended in the 
phased implementation guidelines31 by the Breast Health 
Global Initiative.
The shift in stage at diagnosis modelled in our study 
predicts an absolute reduction in deaths of up to 12%. In 
the context of sub-Saharan Africa, where organised 
population-based screening is not currently feasible, and 
considering that only a small proportion of breast 
cancers are detected through screening, even in settings 
with operational programmes (37% of breast cancers are 
detected through screening in the UK32), downstaging 
needs to be achieved by educating women, the 
community, and health-care providers about breast 
cancer, thus accelerating time-to-presentation and 
referral for diagnosis and treatment. For women of a 
given cancer stage, there will be a large range in the 
duration of the presymptomatic period, because of 
variability in tumour size at symptom recognition, and 
in tumour growth rates. Nevertheless, self-reported time 
to diagnosis remains one of the strongest drivers of late 
stage at diagnosis in all ABC-DO settings, apart from 
Nigeria.27 Between-country differences in cancer stage 
distributions show that accelerating the path to diagnosis 
is not only possible, but it can also be achieved within 
a short (5-year) timeframe, as seen in the ABC-DO-
participating South African hospital, where the 
percentage of women diagnosed with stage III or stage 
IV breast cancer was reduced from 70% to 50%.33 While 
advanced stage led to a high proportion of women dying 
within 6 months of diagnosis in the ABC-DO cohort, 
these deaths included those not recorded as metastatic at 
diagnosis, indicating that underestimating cancer stage 
at diagnosis is prevalent in our data, and implying that 
the real need for and the impact of downstaging on 
survival could be larger still. Under-staging is not 
surprising, given that imaging technologies in this 
setting are overstretched or unavailable. More critically, 
under-staging might also lead to ill-informed and 
inappropriate treatment decisions, with limited benefits, 
large costs, and side-effects for patients.
Improved treatment will lead to an absolute reduction in 
deaths of up to 12%, independent of cancer stage at 
diagnosis. That therapeutic gaps contributed as much to 
low survival as advanced stage warrants immediate action 
to maximise survival gains through early detection 
schemes. This action is needed to ensure that an earlier 
diagnosis is also actively supported to achieve timely access 
to appropriate therapies. Treatment gaps include not only 
women who do not receive either systemic therapy or 
surgery, and the quality and completeness of these 
treatments, but also women who receive no treatment 
whatsoever (14% of women with stage I–III disease).15 
These women tended to be from lower socioeconomic 
groups and believed in traditional medicine.15 Diagnosis 
and therapeutic facilities need to be expanded in terms of 
infrastructure and capacity for immunohistochemistry to 
inform decisions on the use of endocrine therapy, which is 
a more affordable therapy for hospitals in sub-Saharan 
Africa when compared with other therapies (eg, herceptin 
and aromatase inhibitors), and to provide greater access to 
high quality surgery and chemotherapy.
The emerging social inequalities in breast cancer 
survival in sub-Saharan Africa are large, and can 
potentially be tackled through navigational, financial, 
educational, and emotional support. When designing 
interventions to shorten the prediagnostic journey and 
improve treatment access and quality, all women need to 
be reached, including those in rural communities, 
illiterate women, and those who are socioeconomically 
disadvantaged. Provision of universal health coverage, as 
has now been adopted in some sub-Saharan Africa 
countries, will contribute to the alleviation of such 
inequities.
In conclusion, in the decade from 2020 to 2029, a 
projected 416 000 women will die from breast cancer in 
sub-Saharan Africa,1 yet, with downstaging and improved 
treatment, at least a third of these deaths could be 
averted.
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